

**SERVICE DE RHUMATOLOGIE**

**Pr B. Lauwerys**

Pr P. Durez

Pr F. Houssiau

Pr A. Nzeusseu Toukap

Pr M. Stoenoiu

Consultants

Dr L. Méric de Bellefon

Dr A. Durnez

Dr M. Vanthuyne

Brussels, Mai 21<sup>st</sup>, 2019

CONCERNE :

**EudraCT 2017-001619-35**

Etude physiopathologique exploratoire chez cinq patients souffrant de néphrite lupique incidente traités par rituximab en première intention.

Exploratory pathophysiological study in five patients suffering from new-onset lupus nephritis and treated with rituximab as first-line treatment

**Acronyme:** NL-RTX-FIRST

**Protocole :** P1200\_41 Version 1.0. du 14.04.2017

**Sponsor de l'étude :** Cliniques Universitaires Saint-Luc, Bruxelles, Belgique

Dear Madam, Dear Sir,

Please find in attachment to this letter the **DECLARATION OF THE END** of the clinical trial "Exploratory pathophysiological study in five patients suffering from new-onset lupus nephritis and treated with rituximab as first-line treatment"

The study is closed due to the difficulties to recruit patients. No patients were included in the study.

Yours faithfully,

Principal Investigator, Pr Frédéric Houssiau

p/o



Study Coordinator  
Tatiana Sokolova

List of documents in annex:

- Declaration of the End of Trial Form
- Last Annual Report of 12/06/2018